Aarti Drugs Ltd: Stock Analysis & Fundamentals

Updated this week

Aarti Drugs Ltd (Pharma - API) — fundamental analysis, earnings data, and key metrics. PE: 14.9. ROE: 12.7%. This stock is not currently in the Nifty 500 momentum outperformers list.

What's Happening

👔Promoter stake down 0.9% this quarter

🏛️DII accumulation — stake up 2.1%

Key Numbers

Current Price

₹331

Dividend Yield

0.60%

Market Cap

3.0K Cr

Valuation

N/A

Other Top Pharma - API Stocks Beating Nifty 500

Senores Pharmaceuticals Ltd

Average

+8.4%

Ind-Swift Laboratories Ltd

← Back to Pharma - API Dashboard

Frequently Asked Questions: Aarti Drugs Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Aarti Drugs Ltd's latest quarterly results?

Aarti Drugs Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: +10.8%
Revenue Growth YoY: +8.1%
Operating Margin: 9.0%

What is Aarti Drugs Ltd's current PE ratio?

Aarti Drugs Ltd's current PE ratio is 14.9x.

Current PE: 14.9x
Market Cap: 3.0K Cr
Dividend Yield: 0.60%

What is Aarti Drugs Ltd's price-to-book ratio?

Aarti Drugs Ltd's price-to-book ratio is 2.1x.

Price-to-Book (P/B): 2.1x
Book Value per Share: ₹161
Current Price: ₹331

Is Aarti Drugs Ltd a fundamentally strong company?

Aarti Drugs Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): 13.0%

Is Aarti Drugs Ltd debt free?

Aarti Drugs Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹573 Cr

What is Aarti Drugs Ltd's return on equity (ROE) and ROCE?

Aarti Drugs Ltd's return ratios over recent years

FY2023: ROCE 15.0%
FY2024: ROCE 15.0%
FY2025: ROCE 13.0%

Is Aarti Drugs Ltd's cash flow positive?

Aarti Drugs Ltd's operating cash flow is positive (FY2025).

Cash from Operations (CFO): ₹245 Cr
Free Cash Flow (FCF): ₹80 Cr
CFO/PAT Ratio: 146% (strong cash conversion)

What is Aarti Drugs Ltd's dividend yield?

Aarti Drugs Ltd's current dividend yield is 0.60%.

Dividend Yield: 0.60%
Current Price: ₹331

Who holds Aarti Drugs Ltd shares — promoters, FII, DII?

Aarti Drugs Ltd's shareholding pattern (Dec 2025)

Promoters: 55.0%
FII (Foreign): 2.1%
DII (Domestic): 10.1%
Public: 32.7%

Is promoter holding increasing or decreasing in Aarti Drugs Ltd?

Aarti Drugs Ltd's promoter holding has increased recently.

Current Promoter Holding: 55.0% (Dec 2025)
Previous Quarter: 54.7% (Sep 2025)
Change: +0.31% (increasing — positive signal)

Is Aarti Drugs Ltd a new momentum entry or an established outperformer?

Aarti Drugs Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Aarti Drugs Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Aarti Drugs Ltd may be worth studying

Cash flow is positive — CFO ₹245 Cr

What is the investment thesis for Aarti Drugs Ltd?

Aarti Drugs Ltd investment thesis summary:

What is the future outlook for Aarti Drugs Ltd?

Aarti Drugs Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.